Nothing Special   »   [go: up one dir, main page]

BR9915208A - Preparado farmacêutico de moxifloxacina - Google Patents

Preparado farmacêutico de moxifloxacina

Info

Publication number
BR9915208A
BR9915208A BR9915208-8A BR9915208A BR9915208A BR 9915208 A BR9915208 A BR 9915208A BR 9915208 A BR9915208 A BR 9915208A BR 9915208 A BR9915208 A BR 9915208A
Authority
BR
Brazil
Prior art keywords
pharmaceutical preparation
moxifloxacin
preparation
well
moxifloxacine
Prior art date
Application number
BR9915208-8A
Other languages
English (en)
Inventor
Patrick Bosche
Hans Friedrich Mahler
Claus Weisemann
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7889824&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9915208(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of BR9915208A publication Critical patent/BR9915208A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Patente de Invenção: <B>"PREPARADO FARMACêUTICO DE MOXIFLOXACINA"<D>. A presente invenção refere-se a um preparado farmacêutico para a aplicação oral, que contém moxifloxacina, seu sal e/ou hidrato, bem como lactose um processo para a sua preparação, em como o emprego deste preparado para o combate de infecções bacterianas no homem ou nos animais.
BR9915208-8A 1998-11-10 1999-10-29 Preparado farmacêutico de moxifloxacina BR9915208A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19855758 1998-11-10
PCT/EP1999/008230 WO2000027398A1 (de) 1998-11-10 1999-10-29 Pharmazeutische zubereitung von moxifloxacin

Publications (1)

Publication Number Publication Date
BR9915208A true BR9915208A (pt) 2001-07-31

Family

ID=7889824

Family Applications (2)

Application Number Title Priority Date Filing Date
BR9915208-8A BR9915208A (pt) 1998-11-10 1999-10-29 Preparado farmacêutico de moxifloxacina
BRPI9915208-8 BRPI9915208B8 (pt) 1998-11-10 1999-10-29 preparados farmacêutico e de comprimido para a aplicação oral compreendendo moxifloxacina e seu processo de preparação.

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI9915208-8 BRPI9915208B8 (pt) 1998-11-10 1999-10-29 preparados farmacêutico e de comprimido para a aplicação oral compreendendo moxifloxacina e seu processo de preparação.

Country Status (41)

Country Link
US (1) US6610327B1 (pt)
EP (1) EP1128831B1 (pt)
JP (1) JP4809978B2 (pt)
KR (1) KR100650489B1 (pt)
CN (1) CN1149993C (pt)
AR (1) AR021074A1 (pt)
AT (1) ATE279193T1 (pt)
AU (1) AU745282B2 (pt)
BG (1) BG64974B1 (pt)
BR (2) BR9915208A (pt)
CA (1) CA2349161C (pt)
CO (1) CO5070571A1 (pt)
CU (1) CU23260B7 (pt)
CZ (1) CZ292069B6 (pt)
DE (1) DE59910858D1 (pt)
DK (1) DK1128831T3 (pt)
EE (1) EE04418B1 (pt)
ES (1) ES2229786T3 (pt)
HK (1) HK1042245B (pt)
HN (1) HN1999000183A (pt)
HR (1) HRP20010332B1 (pt)
HU (1) HU229065B1 (pt)
ID (1) ID29089A (pt)
IL (2) IL142642A0 (pt)
MA (1) MA26757A1 (pt)
MY (1) MY121114A (pt)
NO (1) NO319342B1 (pt)
NZ (1) NZ511554A (pt)
PE (1) PE20001304A1 (pt)
PL (1) PL194020B1 (pt)
PT (1) PT1128831E (pt)
RU (1) RU2230555C9 (pt)
SI (1) SI1128831T1 (pt)
SK (1) SK283936B6 (pt)
SV (1) SV1999000194A (pt)
TR (1) TR200101310T2 (pt)
TW (1) TW580388B (pt)
UA (1) UA72483C2 (pt)
UY (1) UY25792A1 (pt)
WO (1) WO2000027398A1 (pt)
ZA (1) ZA200103141B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19937116A1 (de) * 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
EP1663226A1 (en) * 2003-09-03 2006-06-07 Ranbaxy Laboratories Limited Pharmaceutical compositions of moxifloxacin and processes for their preparation
WO2006015545A1 (fr) * 2004-08-11 2006-02-16 Shenzhen Tys R & D Co., Ltd. Capsule de gelatine de moxifloxacin et procede pour sa preparation
CN1330306C (zh) * 2004-08-11 2007-08-08 深圳市天一时科技开发有限公司 莫西沙星明胶胶囊剂及其制备方法
CN100363001C (zh) * 2005-09-21 2008-01-23 深圳市天一时科技开发有限公司 一种莫西沙星胶囊剂及其制备方法
WO2007033515A1 (fr) * 2005-09-21 2007-03-29 Shenzhen Tys R & D Co., Ltd. Formulation orale contenant de la moxifloxacine et son procédé de préparation
WO2007033522A1 (fr) * 2005-09-21 2007-03-29 Shenzhen Tys R & D Co., Ltd. Formulation de gélule contenant de la moxifloxacine et son procédé de préparation
US8314122B2 (en) * 2008-10-09 2012-11-20 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Using of organic solvents in wet granulation of moxifloxacin
US20110293717A1 (en) 2008-12-08 2011-12-01 Ratiopharm Gmbh Compacted moxifloxacin
TR200907227A2 (tr) * 2009-09-18 2011-04-21 Bi̇lgi̇ç Mahmut Çözünürlüğü yüksek stabil mikronize granüller.
CN101890169B (zh) * 2009-11-16 2013-09-11 江苏亚邦强生药业有限公司 莫西沙星口服制剂及其制备方法
WO2011086577A2 (en) * 2010-01-12 2011-07-21 Msn Laboratories Limited Pharmaceutical composition of moxifloxacin and its pharmaceutically acceptable salts
CN102247313A (zh) * 2010-06-11 2011-11-23 北京润德康医药技术有限公司 一种以莫西沙星为活性成分的口服缓释固体制剂
CN102247314A (zh) * 2011-01-12 2011-11-23 北京润德康医药技术有限公司 一种以莫西沙星为活性成分的口服固体制剂
EP2510929A1 (en) * 2011-04-11 2012-10-17 Innocoll Technologies Limited Methods for treating bacterial infection
MX2011004759A (es) 2011-05-04 2012-11-21 Senosiain S A De C V Lab Nuevas formas solidas de antibioticos.
RU2466718C1 (ru) * 2011-10-14 2012-11-20 Закрытое акционерное общество "Брынцалов-А" Фармацевтический препарат моксифлоксацина
US9675582B2 (en) 2011-10-25 2017-06-13 U.S. Phytotherapy, Inc. Alternative ACT with natural botanical active GRAS ingredients for treatment and prevention of the Zika virus
WO2013063271A1 (en) * 2011-10-25 2013-05-02 U.S. Phytotherapy, Inc. Artemisinin and berberine compositions and methods of making
CA2853701A1 (en) 2011-10-25 2013-05-02 U.S. Phytotherapy, Inc. Artemisinin and berberine compositions and methods of making
US9358261B2 (en) 2011-10-25 2016-06-07 U.S. Phytotherapy, Inc. Additional artemisinin and berberine compositions and methods of making
BR112014012994A2 (pt) * 2011-11-30 2017-06-13 Toyama Chemical Co Ltd tablete contendo hidrato de metanossulfonato do ácido 1-ciclopropil-8-(difluorometóxi)-7-[(1r)-1-metil-2,3-diidro-1h-isoindol-5-il]-4-oxo-1, 4-diidroquinolina-3-carboxílico
BRPI1106900A2 (pt) 2011-12-26 2013-11-05 Ems Sa Composição farmacêutica sólida compreendendo antibótico da familia das quinolonas e processo de sua obtenção
CN102525982A (zh) * 2012-02-21 2012-07-04 天津市汉康医药生物技术有限公司 一种稳定的盐酸莫西沙星药物组合物
CN102600093B (zh) * 2012-04-11 2013-06-05 南京优科生物医药有限公司 一种莫西沙星片剂及其制备方法
FR2992218B1 (fr) 2012-06-22 2015-01-23 Rivopharm Sa Composition pharmaceutique de chlorhydrate de moxifloxacine et procede de preparation
CN103768063B (zh) * 2012-10-19 2016-04-20 深圳信立泰药业股份有限公司 一种盐酸莫西沙星药物组合物及其制备方法
RU2561037C2 (ru) * 2013-02-07 2015-08-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Антибактериальная фармацевтическая композиция и способ ее получения
WO2015093669A1 (ko) * 2013-12-20 2015-06-25 씨제이헬스케어 주식회사 목시플록사신 수성 제형 및 이의 제조방법
RU2558932C1 (ru) * 2014-05-22 2015-08-10 Открытое Акционерное Общество "Татхимфармпрепараты" Фармацевтическая композиция моксифлоксацина и способ ее приготовления

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3601566A1 (de) * 1986-01-21 1987-07-23 Bayer Ag Pharmazeutische zubereitungen von ciprofloxacin
US5286754A (en) 1986-01-21 1994-02-15 Bayer Aktiengesellschaft Pharmaceutical formulations of ciprofloxacin
JPH01175936A (ja) * 1987-12-28 1989-07-12 Kyorin Pharmaceut Co Ltd ６．８−ジフルオロ−１−（２−フルオロエチル）−１，４−ジヒドロ−７−（４−メチル−１−ピペラジニル）−４−オキソ−３−キノリンカルボン酸を有効成分とする錠剤
DE3906365A1 (de) 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
TW209865B (pt) * 1992-01-10 1993-07-21 Bayer Ag
DE19546249A1 (de) * 1995-12-12 1997-06-19 Bayer Ag Neue Kristallmodifikation des 1-Cyclopropyl-7-([S,S]-2,8-diazabicyclo[4,3,0]non-8-yl)-6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäure Hydrochlorid (CDCH), Verfahren zu dessen Herstellung und diese enthaltende pharmazeutische Zubereitungen
PA8466701A1 (es) * 1998-01-21 2000-09-29 Pfizer Prod Inc Comprimido de mesilato de trovafloxacino

Also Published As

Publication number Publication date
CZ20011652A3 (cs) 2001-08-15
NO319342B1 (no) 2005-07-18
PL348112A1 (en) 2002-05-06
DK1128831T3 (da) 2005-01-17
PL194020B1 (pl) 2007-04-30
HK1042245B (zh) 2005-03-11
WO2000027398A1 (de) 2000-05-18
BRPI9915208A (pt) 2001-07-31
BRPI9915208B1 (pt) 2011-11-01
NZ511554A (en) 2003-07-25
MY121114A (en) 2005-12-30
HN1999000183A (es) 1999-11-01
RU2230555C2 (ru) 2004-06-20
HU229065B1 (en) 2013-07-29
ES2229786T3 (es) 2005-04-16
JP2002529415A (ja) 2002-09-10
PE20001304A1 (es) 2000-12-30
UA72483C2 (en) 2005-03-15
HK1042245A1 (en) 2002-08-09
SI1128831T1 (en) 2005-04-30
HRP20010332B1 (en) 2011-01-31
US6610327B1 (en) 2003-08-26
EE200100259A (et) 2002-12-16
CA2349161C (en) 2008-01-29
ATE279193T1 (de) 2004-10-15
ZA200103141B (en) 2002-05-07
BG64974B1 (bg) 2006-11-30
BG105459A (en) 2001-12-29
JP4809978B2 (ja) 2011-11-09
EP1128831A1 (de) 2001-09-05
CZ292069B6 (cs) 2003-07-16
ID29089A (id) 2001-07-26
KR100650489B1 (ko) 2006-11-28
DE59910858D1 (de) 2004-11-18
NO20012248D0 (no) 2001-05-07
PT1128831E (pt) 2005-01-31
SK283936B6 (sk) 2004-05-04
IL142642A0 (en) 2002-03-10
EE04418B1 (et) 2005-02-15
EP1128831B1 (de) 2004-10-13
TW580388B (en) 2004-03-21
AU1267400A (en) 2000-05-29
CN1325306A (zh) 2001-12-05
IL142642A (en) 2006-10-05
SK6102001A3 (en) 2001-12-03
TR200101310T2 (tr) 2001-10-22
NO20012248L (no) 2001-06-06
KR20010089424A (ko) 2001-10-06
CU23260B7 (es) 2008-01-24
AR021074A1 (es) 2002-06-12
HRP20010332A2 (en) 2002-06-30
SV1999000194A (es) 2000-10-16
RU2230555C9 (ru) 2006-02-27
HUP0104762A3 (en) 2002-10-28
HUP0104762A2 (hu) 2002-05-29
BRPI9915208B8 (pt) 2021-07-06
MA26757A1 (fr) 2004-12-20
UY25792A1 (es) 2001-08-27
AU745282B2 (en) 2002-03-21
CN1149993C (zh) 2004-05-19
CO5070571A1 (es) 2001-08-28
CA2349161A1 (en) 2000-05-18

Similar Documents

Publication Publication Date Title
BR9915208A (pt) Preparado farmacêutico de moxifloxacina
BR0013010A (pt) Formulação de cloreto de sódio de moxifloxacina
BR0111980A (pt) Amina substituìda, composto protegido, métodos para tratar um paciente que tenha ou para prevenir que um paciente contraia uma doença ou condição, para inibir a atividade da beta-secretase, para inibir a clivagem da proteìna precursora de amilóide (app), para inibir a produção do peptìdeo beta amilóide (a beta) em uma célula, para inibir a produção de placa beta0amilóide em um animal, e para tratar ou prevenir uma doença compreendendo depósitos de beta-amilóide no cérebro, composição método para produzir um complexo de beta-secretase, conjunto, e, uso de amina substituìda
BR0214583A (pt) Formulações compreendendo um composto de cefalosporina e seus usos no tratamento de infecções bacterianas em gatos e cães
BR0313164A (pt) compostos com o sistema biciclo[4.2.1] nonano para o tratamento de infecções por flaviviridae
BR0008323A (pt) Derivado de gabapentina para a prevenção e o tratamento de dor visceral
BR0214132A (pt) Composto, processo para a preparação e uso do mesmo, composição farmacêutica, e, método para o tratamento do organismo animal humano ou não humano para combater infecção bacteriana
BRPI0411241A (pt) agentes terapêuticos úteis para o tratamento de dor
BRPI0407662B8 (pt) derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas
BR9911094A (pt) Composições e métodos para o tratamento detosse
BR9917047A (pt) Composto de piperazina, método para prepará-lo, composição farmacêutica contendo-o e seu uso
BR9913337A (pt) Derivados tan-1057
BR0011578A (pt) Utilização do s-enantiÈmero de citalopram para tratamento de distúrbio de ansiedade geral ou ataques de pânico
BR0209206A (pt) Clatrato de hidrato de azitromicina com 1,2-propileno glicol, processo para a sua preparação e composição farmacêutica compreendendo o mesmo
BR0012291A (pt) Fenoxifluorpirimidinas
BR0012942A (pt) Aplicação de flupirtin para a diminuição de dores em doenças articulares degenerativas de cães e gatos
BRPI0418138A (pt) medicamento compreendendo ptx3, sozinho ou em combinação com tsg-6, para tratar doenças degenerativas de cartilagem e ósseas e tratar infertilidade feminina
BR9809457A (pt) Sais de peptìdeo de bpc com atividade organo-protetora, o processo para sua preparação e seu uso em terapia.
BR9913990A (pt) Uso de compostos organofosforados para a produção de preparações farmacêuticas para o tratamento terapêutico e profilático de infecções ou como um fungicida, bactericida ou herbicida em plantas
BR0211358A (pt) Uso do composto de 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-croman o e seus sais fisiologicamente aceitáveis
PT1117409E (pt) Benzenossulfonil (tio) ureias em associacao com betabloqueantes para o tratamento de disfuncoes do sistema nervoso autonomo
PT786998E (pt) A utilizacao de ¬r-(z)|-alfa-(metoxiimino)-alfa-(1-azabiciclo-¬2.2.2|-oct-3-il) acetonitrilo para reduzir a formacao de beta amiloide a4 na doenca de alzheimer
BR0211223A (pt) Derivados de 4-aminociclohexanol substituìdos
BR0213633A (pt) Método e composto para tratar de uma doença associada com recrutamento e/ou ativação aberrante de leucócitos
HUP0003845A2 (hu) Antimikrobiális 8a-azalidok alkalmazása

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BAYER HEALTHCARE AG (DE)

Free format text: TRANSFERIDO DE: BAYER AKTIENGESELLSCHAFT

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE)

Free format text: TRANSFERIDO POR FUSAO DE: BAYER HEALTHCARE AG

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/11/2011, OBSERVADAS AS CONDICOES LEGAIS.

B25D Requested change of name of applicant approved

Free format text: TRANSFERIDO DE: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

B25A Requested transfer of rights approved
B17A Notification of administrative nullity (patentee has 60 days time to reply to this notification)

Free format text: REQUERENTES DA NULIDADE: 1O) HALEX ISTAR INDUSTRIA FARMACEUTICA LTDA. (PETICAO DESP 018120014757); 2O) EMS S/A (PETICAO NPRJ 020120037027).

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/10/99, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 29.10.2019